Raymond James analyst David Novak maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report) today and set a price target of C$8.50. The company’s shares closed last Friday at $4.31.
According to TipRanks.com, Novak is a 3-star analyst with an average return of 4.2% and a 31.7% success rate. Novak covers the Healthcare sector, focusing on stocks such as Antibe Therapeutics, Ziopharm Oncology, and Leap Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knight Therapeutics with a $6.45 average price target, representing a 49.7% upside. In a report issued on September 22, Stifel Nicolaus also upgraded the stock to Buy with a C$6.50 price target.
See today’s analyst top recommended stocks >>
Knight Therapeutics’ market cap is currently $533.6M and has a P/E ratio of 11.00. The company has a Price to Book ratio of 1.43.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KHTRF in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.
Read More on KHTRF:
